DJIA 17,730.11 0.00 0.00%
NASDAQ 5,009.21 0.00 0.00%
S&P 500 2,076.78 0.00 0.00%
market minute promo

4.76 0.00 (0.00%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

OREX $4.76 0.00%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $4.93
Previous Close $4.76
Daily Range $4.72 - $4.93
52-Week Range $3.11 - $9.37
Market Cap $596.0M
P/E Ratio -21.43
Dividend (Yield) $0.00 (0.0%)
Volume 901,050
Average Daily Volume 2,098,642
Current FY EPS -$0.64




Drug Makers

Orexigen Therapeutics, Inc. (OREX) Description

A biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system, disorders, with an initial focus on obesity. Website:

News & Commentary Rss Feed

3 Common Pitfalls Biotech Investors Need to Learn to Avoid

Here is a look at three common mistakes investors make when buying biotech stocks.

Orexigen: Contrave Sales Lead The Sector, But Need Improvement

Belviq Sales Remain Flat- Quarter Over Quarter Will Not Impress

The Anti-Obesity Sector In Q2 Is Not Looking Good

Vivus: Something You Would Want To Know About Qsymia

Vivus- Qsymia Sales Dip From Peak In Previous Week

Orexigen - Contrave Takes Sales Lead In The U.S. - More Sales Still Needed

Arena: Belviq Sales Fall - Belviq Now Outsold By Competition

Why I Found Vivus To Be A Great Investment

Obesity Drugs: Stocks to Watch

Obesity is now considered one of the most serious threats to global health today. To combat this growing pandemic, the Food and Drug Administration has approved four new anti-obesity medications within the past three years. Here is a look at the comparative growth prospects of two of the biotech companies that received the FDA's blessing for their competing diet pills.

See More OREX News...

OREX's Top Competitors

OREX $4.76 (0.00%)
Current stock: OREX
AMGN $153.26 (0.00%)
Current stock: AMGN
GILD $115.04 (0.00%)
Current stock: GILD
BIIB $404.28 (0.00%)
Current stock: BIIB